Axio Research was founded in 1979 by world-renowned epidemiologists and biostatisticians from the University of Washington. Our founders were seeking to create a flexible, responsive organization to facilitate their clinical trials and research. Though we are now an independent, woman-owned business, we have never strayed from our heritage as a responsive, flexible organization committed to the success of our clients.

To be responsive, one must first listen and understand. So that is where we start, by listening to our customers and understanding their goals and timetables. Only then can we hope to match our capabilities to their needs. We like to think right-to-left. In other words, we start from the desired pharmaceutical label or the relevant clinical endpoints and work backward. This enables us to tailor our approach to insure the most efficient and cost effective trial design and conduct.

We tailor our services to accommodate clinical trials from multi-center, multi-thousand patient Phase III pivotal trials to single site, investigator initiated trials. And, as those protocols change or are amended, we rapidly respond to accommodate. We can accomplish this because our Project Directors are empowered to “speak for Axio.” Our Project Directors have the full resources of Axio at their disposal and the authority to use those resources in the pursuit of their client’s goals.

Axio’s Project Directors and staff are committed to our clients’ success. As such, we are committed to delivering, on our client’s timelines, high quality data and thoughtful analysis. That is Axio’s commitment.